Cell cycle growth arrest is an important cellular response to genotoxic stress. Gadd45, a p53-regulated stress protein, plays an important role in the cell cycle G 2 -M checkpoint following exposure to certain types of DNA-damaging agents such as UV radiation and methylmethane sulfonate. Recent findings indicate that Gadd45 interacts with Cdc2 protein and inhibits Cdc2 kinase activity. In the present study, a series of Myctagged Gadd45 deletion mutants and a Gadd45 overlapping peptide library were used to define the Gadd45 domains that are involved in the interaction of Gadd45 with Cdc2. Both in vitro and in vivo studies indicate that the interaction of Gadd45 with Cdc2 involves a central region of the Gadd45 protein (amino acids 65-84). The Cdc2-binding domain of Gadd45 is also required for Gadd45 inhibition of Cdc2 kinase activity. Sequence analysis of the central Gadd45 region reveals no homology to inhibitory motifs of known cyclin-dependent kinase inhibitors, indicating that the Cdc2-binding and -inhibitory domains on Gadd45 are a novel motif. The peptide containing the Cdc2-binding domain (amino acids 65-84) disrupted the Cdc2-cyclin B1 protein complex, suggesting that dissociation of this complex results from a direct interaction between the Gadd45 and Cdc2 proteins. GADD45-induced cell cycle G 2 -M arrest was abolished when its Cdc2 binding motif was disrupted. Importantly, a short term survival assay demonstrated that GADD45-induced cell cycle G 2 -M arrest correlates with GADD45-mediated growth suppression. These findings indicate that the cell cycle G 2 -M growth arrest mediated by GADD45 is one of the major mechanisms by which GADD45 suppresses cell growth.
Normal cells are able to arrest cell cycle progression in response to DNA damage. The control of cell cycle checkpoints has been shown to be associated with the maintenance of genomic fidelity. Defects in the regulation of cell cycle progression may result in genomic instability, i.e. gene mutation, amplification, and chromosomal aberration, which are associated with malignant transformation and tumorigenesis (1) (2) (3) . In addition, the inactivation of cell cycle checkpoint(s) can also have dramatic consequences on therapeutic sensitivity (4, 5) . Cell cycle G 1 -S progression in mammalian cells is controlled by two classes of Cdk inhibitors (6) . One class of inhibitors consists of the INK4 proteins, p16, p15, and p18. The INK4 proteins interact with Cdk4 and Cdk6 preventing the formation of Cdk4-cyclin D and Cdk6-cyclin D complexes as well as subsequent phosphorylation of the retinoblastoma protein (7) (8) (9) . The second class of Cdk inhibitors includes p21 WAF1/CIP1 , p27, and p57 (10 -15) . These proteins are structurally distinct from those of the INK4 family and inhibit a variety of Cdk-cyclin kinases. p21 has been shown to form complexes with Cdkcyclin and inhibit the activity of Cdk4-cyclin D, Cdk6-cyclin D, Cdk2-cyclin E, and Cdc2-cyclin A (12, 13, 16) . In response to DNA damage, p21 is induced in both p53-dependent and p53-independent mechanisms (10, 17) . It has been shown that the disruption of endogenous p21 causes defects in the G 1 cell cycle checkpoint following DNA damage (18, 19) . Therefore, p21 is one of the important regulators in the control of cell cycle progression.
In contrast to the G 1 -S checkpoint, the mechanisms controlling the G 2 -M checkpoint are poorly understood. However, many of the G 2 -M regulators appear to ultimately target Cdc2, a protein kinase required for mitotic entry in mammalian cells (2, 20) . In addition to its association with mitotic cyclins (cyclin B1 and cyclin A), activation of Cdc2 requires phosphorylation at Thr-161 and dephosphorylation at Thr-14/Tyr-15 (2, 20, 21) . Genes that control the G 2 -M checkpoint such as Chk1, Chk2, 14-3-3 , and ATM have been identified in mammalian cells, and these G 2 -M regulators have been highly conserved throughout eukaryotic evolution. It has been shown that Chk1, Chk2, 14-3-3, and ATM alter Cdc2 activity after genotoxic stress by inhibiting dephosphorylation of Cdc25C. The inhibition of Cdc25C prevents the removal of inhibitory phosphorylation from Thr-14 and Tyr-15 of Cdc2 (2, 3, 5) . In addition, DNA damage has been shown to suppress Cdc2 activity by inhibiting the accumulation of cyclin B1 mRNA and protein (22) (23) (24) . Delayed entry into mitosis following DNA damage also correlates with the inhibition of Cdc2-cyclin A kinase activity (25) .
The p53 tumor suppressor protein has been implicated in control of the G 2 -M checkpoint. Overexpression of p53 in p53-deficient human fibroblasts results in both G 1 -S and G 2 -M arrest (26, 27) . The human papilloma virus 16 E6 viral oncoprotein, which blocks p53 function, has been found to decrease the stringency of the mitotic checkpoint (28) . Recent studies have also provided evidence that p53 plays an important role in both the spindle checkpoint and the control of centrosome duplication (29, 30) . In addition 14 -3-3, which blocks Cdc25 activity, has been found to be regulated by p53 (31) . Normal cellular p21 promotes a transient pause late in the G 2 phase (32) . Recent evidence indicates that p53 and p21 WAF1/CIP1 are required for maintaining the G 2 checkpoint in human HCT116 cells (33) . However, the exact role of p53 in the G 2 -M checkpoint is currently under debate (34, 35) . Unlike the p53-regulated G 1 checkpoint, regulation of the G 2 -M checkpoint after DNA damage may be complex and involve redundant controls including p53-independent and p53-dependent mechanisms.
The GADD45 gene has been shown to be induced by a variety of genotoxic agents, e.g. methylmethane sulfonate, UV radiation, hydroxyurea, and ionizing radiation (36, 37) . Induction of GADD45 by ionizing radiation is regulated transcriptionally by p53 via a p53-binding site in the third intron of GADD45 (38) and strictly depends on normal cellular p53 function (39) . With DNA base-damaging agents, p53 is not required for GADD45 induction but p53 can contribute to its responses (40) . The Gadd45 nuclear protein has been shown to accumulate following DNA damage. Gadd45 binds to proliferating cell nuclear antigen and to p21 proteins, although the biological relevance of these physical interactions remains to be determined (41) (42) (43) (44) . Recently Gadd45 protein has been reported to interact with multiple cellular proteins including Cdc2 protein kinase (45) , core histones (46) , and MTK1/MEKK4 1 (47) . These findings indicate that Gadd45 may play important roles in cell cycle control, DNA repair, and the regulation of signaling pathways.
We have previously reported that transient transfection with GADD45 expression vectors in a variety of cell lines can suppress cell growth (48) . However, the mechanism(s) by which GADD45 negatively controls cell growth is unclear. It was recently reported that microinjection of a GADD45 expression vector into human normal fibroblasts causes G 2 -M arrest and that cells with disrupted GADD45 exhibit a defective G 2 -M checkpoint following DNA damage (49) . Consistent with these findings, the Gadd45 protein has been shown to interact with Cdc2 and inhibit Cdc2 kinase activity (45) . In the present report, we have identified the central region of Gadd45 required for the interaction of Gadd45 with Cdc2 protein and for the inhibition of Cdc2 kinase activity. This region is also essential for the Gadd45-induced dissociation of the Cdc2-cyclin B1 complex and cell cycle G 2 -M arrest. Importantly, the GADD45-induced G 2 -M arrest was found to correlate with GADD45-mediated cell growth suppression, indicating that the role of GADD45 in the control of cell cycle arrest may be one of the major mechanisms by which GADD45 suppresses cell growth.
EXPERIMENTAL PROCEDURES
Construction of Gadd45 Deletion Mutants-To construct the Myctagged Gadd45 deletion expression vectors, a series of Gadd45 primers was designed to contain an in-frame 5Ј NdeI site and to amplify specific regions of the human GADD45 cDNA construct, pHul45B2 (37) . Polymerase chain reaction products were cloned into the pcrII vector using the TA kit (Invitrogen, Carlsburg, CA) and sequenced prior to subcloning into NdeI/XhoI-digested pCS2MT vector. Expression of this Gadd45 construct tagged with six copies of the Myc epitope was monitored by the 9E10 anti-Myc monclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA).
For deletion from the amino terminus, the carboxyl-terminal Gadd45 primer CCTCTAGATGCCATCACCGTTCAGGG was used in combination with the internal amino-terminal primers as indicated: Gadd45-(48 -166), GCGGCCCATATGCTCAACGTCGACCCC and Gadd45-(74 -166), GGCTCTGCATATGCACTTCACCC. For deletions from the carboxyl terminus, the amino-terminal primer CCGGAAGCTTGCCA-TATGACTTTGGAGG was used in combination with the internal carboxyl-terminal primers as indicated: Gadd45-(1-71), CAGGGTGA-AGTGGATCTAGAGAGCC; Gadd45-(1-96), GCAGGAGCTCCGCCAT-CTAGACCGGG; and Gadd45-(1-124), GGATTCGTCACCATCTAGAA-GTGCAGG.
Synthesis of Peptides-An overlapping Gadd45 peptide library was synthesized using standard Fmoc (N-(9-fluorenyl)methoxycarbonyl) chemistry on a Perkin-Elmer/AB model 433A automated synthesizer. The peptides were purified by reverse phase high pressure liquid chromatography with structure confirmed by fast atom bombardment mass spectrometry and amino acid analysis, as described previously (51) .
The Gadd45 Cell Culture and Transfection-The human colon carcinoma line RKO was grown in RPMI 1640 medium supplemented with 10% fetal bovine serum. For cell transfection with Myc-tagged Gadd45 deletion expression vectors, RKO cells (10 6 ) were seeded onto a 10-mm plate before transfection. For each plate, 5 g of DNA and 15 l of LipofectAMINE (Life Technologies, Inc.) were added to 300 l of Opti-MEM (Life Technologies, Inc.) in separate tubes. The solutions were mixed gently, incubated for 15 min at room temperature, diluted with 2.4 ml of Opti-MEM, added to the plates, and incubated for 6 h at 37°C. Equal volumes of medium with 10% fetal calf serum were added, and the plates were incubated overnight. Fresh medium was added the next day, and cells were harvested after 48 h.
Cellular Protein Preparation, Immunoprecipitation, and Western Blotting Assay-At 48 h post-transfection, plates were rinsed with PBS, and cells were lysed in PBS lysis buffer with 100 g/ml phenylmethylsulfonyl fluoride, 2 g/ml aprotinin, 2 g/ml leupeptin, and 1% Nonidet P-40. Lysates were collected by scraping and cleared by centrifugation at 4°C. For immunoprecipitation, cellular lysates were incubated with 10 l of antibody and 20 l of protein A/G-agarose beads (Santa Cruz Biotechnology) at 4°C for 4 h. Immunocomplexes were washed 4 times with lysis buffer, loaded onto a 12% SDS-polyacrylamide gel, and transferred to Protran membranes. Membranes were blocked for 1 h at room temperature with 5% milk, washed with PBS-T (PBS with 0.1% Tween 20), and incubated with the 9E10 anti-Myc antibody for 2 h. Membranes were washed 4 times in PBS-T, and horseradish peroxidase-conjugated anti-mouse antibody was added at a 1:4000 dilution in 5% milk. After 1 h, membranes were washed, detected by ECL (Amersham Pharmacia Biotech), and exposed to x-ray film (Eastman Kodak Co.).
ELISA Assay-Immulon II immunoabsorption plates (Dynatech) were coated with 500 ng of Gadd45 peptides in PBS and incubated overnight at 4°C. After rinsing with PBS-T (PBS with 0.05% Tween 20) and blocking in 5% nonfat milk in PBS-T, 40 ng of purified Cdc2-cyclin B1 (Upstate Biotechnology Inc., Lake Placid, NY) protein was added. Following incubation for 1 h at room temperature, the plates were washed, and anti-Cdc2 antibody (Santa Cruz Biotechnology) was added at a 1:1000 dilution. After incubation for 1 h at room temperature, the plates were washed, and horseradish peroxidase-conjugated anti-rabbit antibody was added. Following incubation, the one-step TMB solution (Pierce) was added for development. Optical density was measured using a plate reader.
Growth Suppression Assay-Human colorectal carcinoma RKO cells were transfected with Myc-tagged Gadd45 expression vectors and selectable marked vector (pSV2neo) at a 10:1 ratio by the calcium phosphate method as described previously (48) . Following a 2-week selection with 400 g/ml G418, cells were fixed at 14 days and scored for colonies containing at least 50 cells.
Cdc2 Kinase Assay-Purified Cdc2-cyclin B1 complex (100 ng) was incubated with the indicated amounts of recombinant Gadd45 protein or Gadd45 peptides for 10 min. Histone H1 kinase assays were then performed in the presence of 10 g of histone H1 (Upstate Biotechnology, Inc.), 15 mM MgCl 2 , 7 mM ␤-glycerol phosphate, 1.5 mM EDTA, 0.25 mM sodium orthovanadate, 0.25 mM dithiothreitol, and 10 Ci of
␥-[
32 P]ATP in a 30-l volume. After 15 min at 30°C, 10-l aliquots were spotted on phosphocellulose paper and then washed 3 times with 0.75% phosphoric acid. After an acetone rinse, the radioactivity was measured by scintillation counting.
Flow Cytometry Analysis-Human colorectal carcinoma RKO cells were plated into 100-mm dishes at a density of 10 6 16 h prior to transfection. RKO cells were cotransfected with the Myc-tagged Gadd45 and CD20 expression vectors at a ratio of 10:1. In each plate, 10 g of plasmid DNA and 15 l of LipofectAMINE (Life Technologies, Inc.) were added to 300 l of Opti-MEM in separate tubes. The solutions were mixed gently, incubated for 15 min at room temperature, diluted with 2.4 ml of Opti-MEM, added to the plates, and incubated for 6 h at 37°C. Equal volumes of medium with 10% fetal calf serum were added, and the plates were incubated overnight. Fresh medium was added the following day. Forty-eight hours post-transfection, cells were collected with 0.1% EDTA-PBS buffer, incubated with fluorescein isothiocyanate-conjugated CD20 antibody in the presence of 1% fetal bovine serum, fixed with 70% ethanol for 2 h at 4°C, and washed with PBS. Cells were then incubated with RNase (10 g/ml) for 30 min and stained with propidium iodide (Sigma) at 50 g/ml. Cell cycle analysis was performed using the Becton Dickinson FACScan. The Gadd45-expressing cells were sorted by gating the CD20-positive population. At least 5000 fluorescein isothiocyanate-positive cells were analyzed using CellQuest and Modfit programs.
RESULTS

A Central Region of Gadd45 Protein Is Required for Cdc2
Binding-Our recent work demonstrates that the Gadd45 protein physically associates with Cdc2 (45) . We subsequently sought to map the regions of the Gadd45 protein involved in Cdc2 binding using a series of Myc-tagged Gadd45 deletion protein expression vectors. Cellular lysates from human colorectal carcinoma RKO cells transfected with Myc-tagged Gadd45 deletion vectors or vector controls were immunoprecipitated with anti-Cdc2 and anti-Myc antibodies. Following immunoblotting analysis, the Myc-tagged Gadd45 proteins were detected in both cell lysates and immunoprecipitated complexes with anti-Myc antibody. Fig. 1A shows abundant expression levels of Myc-tagged Gadd45 deletion proteins in transfected RKO cells. Following immunoprecipitation with anti-Cdc2 antibody, full-length Myc-tagged Gadd45 protein was detected. Deletion of the carboxyl terminus of Gadd45 in Gadd45-(1-124) and Gadd45-(1-96) did not interfere with the interaction between Gadd45 and Cdc2. Deletion of the amino terminus in Gadd45-(48 -166) also showed a normal binding activity for the interaction between Gadd45 and Cdc2. However, Gadd45-(74 -166) appeared to be deficient in Cdc2 binding activity. Taken together with our previous finding that recombinant Gadd45-(1-71) protein fails to bind to Cdc2 (45), these results indicate that the central region of the Gadd45 protein (amino acids 71-96) is required for Cdc2 binding.
To further examine the Gadd45 domain involved in Cdc2 binding, ELISA assays were performed using a series of Gadd45 peptides. The Gadd45 protein sequence was divided into a series of 20-residue peptides with a 4-residue overlap between each contiguous peptide. In these experiments, recombinant full-length and two truncated Gadd45 proteins were included as controls for the interaction between Gadd45 and Cdc2. Consistent with our previous findings, both full-length Gadd45 and Gadd45-(1-124) proteins displayed a strong interaction with Cdc2 whereas the Gadd45-(1-71) deletion protein did not exhibit Cdc2 binding activity. In the initial screening of the Gadd45 peptides, Gadd45-Cdc2 binding activity was mapped to a domain between Gadd45 amino acids 65 and 84 (Fig. 1B, Gadd45-(65-84) ). This region was examined with three additional peptides to further localize the binding do- main: Gadd45-(69 -84), Gadd45-(61-80), and Gadd45-(61-71). When smaller regions of the (65-84) domain were analyzed individually in peptides Gadd45-(61-71) and Gadd45-(69 -84), none of the peptides were able to bind Cdc2. Interestingly, as deletion of the final four amino acids of the peptide in peptide Gadd45-(61-80) also abolished Cdc2 binding activity. This deletion removed two cysteines that might be involved in a nonspecific interaction. However, these two cysteines alone do not account for Gadd45 binding to Cdc2, because the Gadd45-(69 -84) peptide failed to bind Cdc2.
The Cdc2 Binding Motif of Gadd45 Is Required for the Gadd45 Inhibitory Effect on Cdc2
Kinase Activity-Gadd45 inhibition of Cdc2-cyclin B1 kinase activity may be mediated through its physical interaction with the Cdc2 protein (45) . To identify the Cdc2-inhibitory domain of Gadd45, we tested the ability of the Gadd45 peptides to inhibit Cdc2-cyclin B1 kinase activity. As shown in Fig. 2 , full-length recombinant Gadd45 protein strongly inhibited the histone H1 kinase activity of the purified Cdc2-cyclin B1 complex. In contrast, the Gadd45-(1-71) deletion protein (containing residues 1-71) failed to inhibit Cdc2-cyclin B1 activity. The inhibitory effect on Cdc2 kinase activity was only seen with the Gadd45-(65-84) peptide, which contains the Gadd45 region required to bind Cdc2. The other peptides spanning different regions of the Gadd45 protein failed to inhibit Cdc2 kinase activity. Similar to the results in Fig. 1B , neither half of the amino acid 65-84 region in peptides Gadd45-(61-71) and Gadd45-(69 -84) was able to inhibit Cdc2 kinase activity. The Gadd45-(61-80) peptide with deletion of the final four amino acids of the Gadd45-(65-84) also failed to suppress Cdc2 kinase activity. These results indicate that the Cdc2-binding and -inhibitory domains on Gadd45 are in the same region of the protein (Fig. 3) .
The Cdc2-interacting Domain of Gadd45 Mediates Dissociation of the Cdc2-Cyclin B1 Complex-Gadd45 is able to dissociate the Cdc2-cyclin B1 complex, which in turn leads to inhibition of Cdc2-cyclin B1 kinase activity (45) . Because Gadd45 only interacts with Cdc2 protein (45), the possibility was considered that Gadd45 disrupts the Cdc2-cyclin B1 complex through its direct association with Cdc2. To test this hypothesis, a "wash off assay" was performed. In the experiment, the Cdc2-cyclin B1 immunocomplex was precipitated with anticyclin B1 antibody, washed with lysis buffer, and then with kinase buffer. The immunocomplexes were incubated with the indicated amounts of Gadd45 peptides. The complexes were then washed and analyzed by SDS-PAGE and immunoblotting with anti-Cdc2 antibody. The expectation was that if Gadd45 interaction with Cdc2 led to disruption of the Cdc2-cyclin B1 complex then the second wash should remove dissociated Cdc2 from the immune complexes. Increasing amounts of the Gadd45-(65-84) peptide containing the Cdc2 binding region reduced the Cdc2 protein level in the complexes, whereas the peptides Gadd45-(49 -68) and Gadd45-(81-100) had no effect (Fig. 4) . As a positive control, full-length Gadd45 protein showed strong dissociative activity with regard to the Cdc2-cyclin B1 complex. Furthermore, equivalent levels of cyclin B1 were observed with immunoblotting. Therefore, the Gadd45-Cdc2-binding domain is essential for dissociation of the Cdc2-cyclin B1 complex.
Abrogation of the Cdc2 Binding Activity Disrupts Gadd45 Induction of Cell Cycle G 2 -M Arrest-Expression of the Gadd45
protein has been shown to arrest cells in early M phase (49) . To   FIG. 2 . In vitro mapping of the Cdc2-inhibitory domain of Gadd45 protein. Purified Cdc2-cyclin B1 complexes (100 ng) were incubated with 500 ng of Gadd45 peptides, and histone H1 kinase assays were then performed as described under "Experimental Procedures." Following histone H1 kinase reaction, 20 l of aliquots were spotted on phosphocellulose paper and washed 3 times with 0.75% phosphoric acid. After an acetone rinse, the radioactivity was measured by scintillation counting. The quantitative results are the average of three separate experiments. As the positive controls, Gadd45 and its deletion protein Gadd45-(1-71) were included in the experiments. Bars indicate ϮS.D.
FIG. 3. Localization of the Cdc2-binding and -inhibitory domains in Gadd45.
A linear map of the Gadd45 protein with numbers representing amino acid positions is shown. A, using fulllength recombinant and truncated Gadd45 proteins, the degree of Cdc2 interaction and inhibition is shown with (ϩ) and (Ϫ). The region from amino acid 71 to 124 is required for both. B, using Myctagged Gadd45 deletion mutant proteins, the Cdc2-binding domain was further localized to the central region (amino acids 71-96) of Gadd45. C, with screening of the Gadd45 peptide library, the Cdc2-binding and -inhibitory domains in Gadd45 were identified within the region spanning amino acids 65-84. determine whether loss of the Cdc2 binding region on Gadd45 would abolish the ability of Gadd45 to induce cell cycle G 2 -M arrest, several Gadd45-expressing vectors, some of which contain incomplete Cdc2-binding domains, were utilized for cell cycle analysis. Human RKO cells were cotransfected with Myctagged Gadd45 deletion vectors and CD-20 expression vectors. After 48 h, cells were harvested, and the CD-20 positive cell population was subjected to FACScan analysis. Cells transfected with vector control and untreated RKO cells displayed similar cell cycle distributions (Table I) . With overexpression of full-length Gadd45 protein, a substantial increase in the G 2 -M population (33.5%) was evident when compared with the vector-transfected cell (18.6%). Similarly, cells transfected with the Gadd45-expressing deletion vectors that contained the intact Cdc2-inhibitory domain also revealed a higher G 2 -M accumulation (29.8% for Gadd45-(1-124), 28.5% for Gadd45-(1-96), and 27.3% for Gadd45-(48 -166)), whereas cells expressed with the incomplete Cdc2-inhibitory domain (Gadd45-(1-71) and Gadd45-(74 -166)) did not exhibit the Gadd45-induced cell cycle arrest at G 2 -M phase.
GADD45 Inhibition of Cdc2 Kinase Correlates with GADD45-induced Growth Suppression-Expression of Gadd45
protein leads to cell growth suppression (48) . The growth suppression has been thought to be caused at least in part by GADD45-mediated G 2 -M arrest. To identify the regions of Gadd45 protein that contain growth inhibitory properties, a short term growth assay was performed. Myc-tagged Gadd45 expression vectors were cotransfected with pSV2neo vector and selected in medium containing G418. After 2 weeks, cell colonies were fixed and stained for cell growth analysis. As shown in Fig. 5, A and B, Gadd45 reduced RKO colony formation to approximately one-fourth of that seen with the vector control. As expected, growth suppression generated by the tumor suppressor p53 was much greater; it reduced colonies to onetwentieth of the vector control. Consistent with GADD45-mediated G 2 -M arrest, Gadd45-(1-124) displayed strong growth suppression (25.2% colony formation). Gadd45-(1-96) and Gadd45-(48 -166), both of which contain the intact Cdc2-inhibitory domains, exhibited growth suppression (about 34% colony formation). In contrast, disruption of the Cdc2-inhibitory domains substantially abrogated growth suppressive potential in Gadd45-(1-71) and Gadd45-(74 -166), indicating that a direct interaction of Gadd45 protein with Cdc2 and inhibition of Cdc2 activity are important for GADD45-mediated growth suppression. However, growth suppression by GADD45 may also involve other mechanisms in addition to induction of G 2 -M arrest because disruption of the Cdc2-inhibitory domain in the Gadd45 protein did not completely abrogate GADD45-mediated growth suppression. Both Gadd45-(1-71) and Gadd45-(74 -166) still suppressed cell growth by approximately 35% (about 65% colony formation) in the RKO line. FIG. 4 . Dissociation of Cdc2-cyclin B1 complex by Gadd45 protein and peptides. Cellular protein was prepared from human colorectal carcinoma RKO cells and followed by a "wash-off assay" (see "Experimental Procedures"). The Cdc2-cyclin B1 complex was immunoprecipitated by anti-cyclin B1 antibody and incubated with the indicated amounts of recombinant Gadd45 protein or synthetic peptides. Following incubation, immunoprecipitated complexes were washed again with lysis buffer to remove dissociated protein and analyzed by SDS-PAGE. The immunoblotting was detected with monoclonal antiCdc2 antibody. As a loading control, an aliquot of the immunoprecipitates was analyzed by anti-cyclin B1 antibody and is shown in the lower panel. 
DISCUSSION
In this report, detailed studies were undertaken to define the regions involved in the interaction between Gadd45 and Cdc2 proteins (Fig. 3) . Using Myc-tagged Gadd45 deletion fusion proteins combined with peptide ELISA analysis, it has been shown that the central region of Gadd45 between amino acids 65 and 84 contains a high affinity Cdc2-binding domain. This Cdc2 binding motif is also required for the inhibitory effect by Gadd45 on Cdc2-cyclin B1 kinase activity (Fig. 3) . In support of our previous finding that recombinant Gadd45 protein disrupts the Cdc2-cyclin B1 complex, Gadd45 peptides containing the Cdc2-interacting domain were capable of dissociating the Cdc2-cyclin B1 complex, suggesting that dissociation of this complex by Gadd45 protein resulted from a direct interaction of Gadd45 with Cdc2. As expected, the Cdc2 binding and inhibitory motif on Gadd45 was shown to be required for its induction of cell cycle G 2 -M arrest. Furthermore, a short term cell survival assay demonstrates that the Cdc2-inhibitory domain of Gadd45 protein contributes substantially to growth suppression, indicating that Gadd45-induced growth arrest correlates with the GADD45-mediated cell cycle G 2 -M arrest.
Introduction of Gadd45 into tumor cells by transient transfection results in growth suppression (48) . However, the mechanism by which Gadd45 inhibits cell growth remains to be further defined. Recent findings have demonstrated that overexpression of Gadd45 in human normal fibroblasts causes cells to arrest in the early mitotic phase. Cells with disrupted endogenous Gadd45 expression display abrogation of the cell cycle G 2 -M checkpoint following exposure to certain DNA-damaging agents (49) . In support of these observations, Gadd45 has been shown to interact with Cdc2 protein kinase, which is required for the G 2 -M transition. The interaction between Gadd45 and Cdc2 results in inhibition of Cdc2-cyclin B1 kinase activity (45) . Importantly, primary cells from gadd45 Ϫ/Ϫ mice exhibit genomic instability and abnormal mitotic morphology (50) . Taken together, these findings implicate GADD45 as an important regulatory component in the G 2 -M cell. It is thus evident that the GADD45-mediated G 2 -M arrest may greatly contribute to the growth-suppressive capability of Gadd45. In addition, Gadd45 has recently been found to associate with MEKK4 kinase (47) , an upstream component of JNK kinase, and to activate JNK-dependent apoptosis. Therefore, it can be postulated that both the GADD45-mediated G 2 -M cell cycle arrest and GADD45-activated apoptosis may play a role in the control of cell growth following genotoxic stress. However, in the human RKO cell line that was used in this study, apoptosis caused by overexpression of GADD45 was not observed (data not shown), suggesting that GADD45-mediated apoptosis might be limited in certain types of cell lines.
The central region of Gadd45 that is required for inhibition of Cdc2 exhibits no homology to the inhibitory motifs of known cyclin-dependent kinase inhibitors, suggesting that the Cdc2-inhibitory domain of Gadd45 might be a novel motif. Future studies will employ site-directed mutagenesis to determine the specific amino acids involved in Cdc2 kinase inhibition. In addition to the interaction with Cdc2 protein kinase, Gadd45 is able to associate with several cellular proteins, including p21 WAF1/CIP1 (43) , proliferating cell nuclear antigen (41), core histone protein (46) , and MTK1/MEKK4 (47) . The presence of Gadd45 in these protein complexes indicates that Gadd45 can play important roles in the control of cell cycle progression, DNA repair, apoptosis, and the regulation of signaling pathways. Interestingly, the p21-interacting domain of Gadd45 was recently mapped to the same region as the Cdc2-binding domain. 2 Therefore, it can be predicted that the central region of Gadd45 may serve as an important "core" through which Gadd45 is able to cross-talk with other cell cycle regulators. Finally, those interactions can coordinate the regulation of cell cycle checkpoints following genotoxic stress.
The results in Fig. 4 present direct evidence that dissociation of Cdc2-cyclin B1 by Gadd45 requires a physical interaction between Gadd45 and Cdc2 protein. Destruction of the Cdc2 binding motif in Gadd45 peptides impaired their ability to disrupt Cdc2-cyclin B1. In fact, there is no evidence that Gadd45 has phosphatase, kinase, or protease properties. Therefore, the inhibition of Cdc2 kinase activity can be pictured as a result of the physical interruption of the Cdc2-cyclin B1 complex by Gadd45. Consistent with those results, Table I demonstrates that deletion constructs of Gadd45 that lack the Cdc2-binding and -inhibitory regions failed to arrest cells in cell cycle G 2 -M. Three deletion proteins, Gadd45-(1-124), Gadd45-(1-96), and Gadd45-(48 -166), all of which contain the intact Cdc2-binding and -inhibitory domains, were capable of arresting RKO cells at G 2 -M transition. In contrast, Gadd45-(1-71) and Gadd45-(74 -166) were not able to induce G 2 -M arrest. Importantly, the GADD45-activated cell cycle G 2 -M arrest was found to mediate the GADD45-induced cell growth suppression. Disruption of the Cdc2-binding domain in Gadd45-deletion proteins substantially abrogated GADD45-induced cell growth suppression (Fig. 5) . However, because fulllength Gadd45 protein generated a greater growth inhibition than those seen in Gadd45-deletion proteins, it is suggested that the entire contiguous Gadd45 protein might be required for maximal growth suppression.
In conclusion, we have identified a novel motif that is required for the interaction of Gadd45 with Cdc2 protein and the inhibitory effect of Gadd45 on Cdc2 kinase activity. We have also confirmed that Gadd45 dissociates the Cdc2-cyclin B1 via this interacting domain. Importantly, this motif was found to be necessary for both Gadd45-induced G 2 -M arrest and growth suppression, indicating that the Gadd45-mediated cell cycle arrest correlates with the growth suppression by GADD45. These findings have provided mechanistic insight into the biological significance of the Cdc2-interacting domain on Gadd45 and implicate Gadd45 as an important component in regulating cell cycle progression.
